Do you have the skills to help us push the boundaries in drug discovery by developing and implementing in vitro metabolic cell models and assays? Do you also believe that the chances of real scientific progress are at their best when we collaborate closely and cross-functionally? Then you may be one of the two Research Scientists we would like to welcome to our team. About Novo Nordisk Research Centre Oxford (NNRCO)
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. We employ more than 42,000 people in 80 countries and market our products in around 170 countries. Novo Nordisk Research Centre Oxford (NNRCO) is Novo Nordisk’s Translational Research Unit focused on biology and target discovery across the broad spectrum of cardiometabolic disease in Oxford, United Kingdom. Our location in the heart of the University of Oxford medical campus enables two-way collaborations with some of the best medical scientists in the world. We use genetics, functional genomics, human-centric disease models and computational biology to develop an unparalleled understanding of cardiometabolic disease and deliver therapies that transform the lives of patients.
You can read more about Novo Nordisk Research Centre Oxford at: http://www.novonordisk.co.uk/about-novo-nordisk-in-uk/oxford-research-centre.html About the Department The Department of Discovery Technologies and Genomics has as its mission to establish and apply state-of-the-art genomics and screening technologies to discover and validate novel therapeutic targets for cardiometabolic diseases using human-centric in vitro approaches. Ultimately, our aim is to identify targets and key biology to discover new disruptive therapeutics.
The department is led by Carina Ämmälä, and consists of specialists, staff scientists and post-doctoral scientists. We are a dedicated, collaborative team, working within a variety of advanced technologies, including high throughput screening, high content imaging, single-cell sequencing, CRISPR editing, functional genomics, proteomics, peptidomics, and statistical modelling. Together, we share a passion for translational research and a desire to discover new scientific paths to improve the lives of patients.
The position We are looking for two Research Scientists to support our target discovery research. The primary goal in both positions will be to establish in vitro assays in primary human cell types relevant cardiometabolic disease, assays that will be used for identification and validation of novel innovative drug targets for treating cardiometabolic disease. You will be expected to use your cell and molecular biology skills to develop novel disease-relevant phenotypic cellular assays used in screening to identify novel targets, and for mechanism of actions studies to increase the biological understanding of promising targets. Moreover, there is a significant element of close collaboration within the NNRCO and with external partners. In the NNRCO you will work closely with automation and imaging experts to miniaturize, automate and optimize assays for high-throughput screening. You will also work with geneticists and computational scientists to develop data compelling packages and building evidence for clinical benefit to support target selection. Outside the NNRCO, you will engage with external partners through collaborations with universities and/or biotech companies. Finally, it is expected that the position holder show leadership within their field of expertise and mentor post docs and junior scientists. All of the above applies for both open positions, and we are very open to adjusting some aspects of the roles to fit your unique experience. Likewise, in this position you will also have the opportunity to propose and pursue your own scientific ideas aligned with the NNRCO ambition. Qualifications The ideal candidate holds a PhD in molecular/cellular biology or related life science with significant experience working with human primary cells and cell-based assay development along with knowledge of the cellular/molecular mechanisms within an area related to cardiometabolic disease. Some relevant cell types and tissues are adipocytes, hepatocytes, Stella the cells, islet of Langerhans, kidney, muscle, and vascular cells. In addition, experience with vitro co-cultures and organoid models would be considered a plus. Hands on experience of additional technologies such as confocal imaging, flow cytometry, mass spectrometry or state of the art sequencing methodologies is desirable, and knowledge of the drug discovery process and in vitro screening systems (i.e. high-throughput screening) is an advantage. Both positions are lab based, so it is essential that candidates have a strong motivation for working hands-on in the lab, progressing science through well designed and robust in vitro experimental work. We always have several projects running, so we are looking for candidates who thrive working on multiple projects simultaneously and who can keep their cool even when there is pressure to deliver. Importantly, the right candidates will have a collaborative behaviour, and an entrepreneurial mindset. Salary indication: GBP 47.000 – 52.000 yearly Contact For further information, please contact Director Carina Ämmälä on +44 782 460 6940